3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
3
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Cisplatin
55
Radiotherapy
33
Cetuximab
25
Paclitaxel
23
Carboplatin
23
Radiotherapy, Intensity-Modulated
21
pembrolizumab
19
Docetaxel
17
Fluorouracil
16
Nivolumab
14
Drug Therapy
11
Radiation
9
Erlotinib Hydrochloride
8
Blood Specimen Collection
8
durvalumab
7
Magnetic Resonance Spectroscopy
7
Surveys and Questionnaires
6
atezolizumab
5
Surgical Procedures, Operative
5
Radiosurgery
5
Esophagectomy
5
Chemoradiotherapy
5
olaparib
4
dacomitinib
4
Leucovorin
4
Cyclophosphamide
4
Capecitabine
4
Biopsy
4
Afatinib
4
fludarabine phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Squamous Cell
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled